| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ABIOMED INC | 1,450,000 | 186,441,000 | 38.79% | ||
| 2 | ENTELLUS MEDICAL INC | 3,813,197 | 84,577,000 | 17.60% | ||
| 3 | REVANCE THERAPEUTICS INC COM | 4,592,047 | 74,437,000 | 15.49% | ||
| 4 | CORIUM INTERNATIONAL INC | 9,353,304 | 52,659,000 | 10.96% | ||
| 5 | AXOGEN INC | 4,861,111 | 43,896,000 | 9.13% | ||
| 6 | ENDOLOGIX INC | 1,257,468 | 22,855,000 | 4.76% | ||
| 7 | MEDICINOVA INC COM NEW | 1,170,370 | 8,766,000 | 1.82% | ||
| 8 | ACURA PHARMACEUTICALS INC | 1,956,397 | 3,130,000 | 0.65% | ||
| 9 | LIGAND PHARMACEUTICALS INC | 32,893 | 2,400,000 | 0.50% | ||
| 10 | Catalyst Biosciences | 1,179,352 | 1,448,000 | 0.30% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001172661-16-004243, filed 2016.11.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
